LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Response to the Public Consultation on Blood, tissues and cells for medical treatments & therapies

16/04/2021
FEEDBACK

EuropaBio Response to the Public Consultation on Blood, tissues and cells for medical treatments & therapies ’

Brussels, 16 April 2021 -EuropaBio sent the response to the European Commission’s public consultation on the use of blood, tissues and cells for medical treatments and therapies (hereafter, BTC). Representing developers of cell-based and plasma-derived medicinal products, EuropaBio advocates the European Union’s uptake of transformative advanced therapies which hold a great potential for the health and wellbeing of patients and the sustainability of healthcare systems. EuropaBio believes, that while the Commission consultations cover the full scope of the BTC legislation, there is need for bespoke policies for different categories of products.

Cell-based medicinal products
A revision of the BTC legislation should address the existing inconsistencies within the regulatory framework and set clear boundaries between the legislation for human medicinal products and the BTC legislation. For example, some advanced therapy medical products (hereafter, ATMPs) are at the borderline between the two frameworks which creates administrative burden for many sector’s developers. The BTC legislation should apply up to the point of procurement and testing of the drug substance. Once the drug product enters manufacturing, the available ATMP guidance applies. Moreover, the BTC legislation should clarify the minimum requirements for donation, procurement and testing in cases where human tissues and cells are used as a starting material for ATMPs. The lack of harmonisation at national level should also be addressed. Existing practice shows that very often multiple responsible authorities are assigned for both facility licensing and inspections procedures. More harmonisation is needed also on international level. In addition, the new framework should be adaptive to new scientific and technical developments in the field of ATMPs and any new EU-level requirements should be justified.

Plasma-derived medicinal products
Therapy developers need to collect sufficient plasma to manufacture plasma-derived therapies to meet the needs of European patients and mitigate the possible supply disruptions which increases a dependency from the third countries. We, therefore, call on the EU to take a leadership role in supporting Member States to increase their plasma collection. We need a framework that differentiates between whole blood for transfusion and plasma for fractionation and develops bespoke rules and allows the coexistence of public sector and private sector plasma collection centres as well as compensation of donors for the expenses and inconvenience related to the donation. A constant development of science and innovation requires consistent updates of testing requirements. EuropaBio suggests creating a clear mechanism to facilitate this process. The relevant expert bodies such as the European Centre for Disease Prevention (ECDC) or the European Directorate for the Quality of Medicines (EDQM) or any other EU body could help to ensure that pace with scientific innovation can be kept while avoiding the potential delays of updates via legislation.

Download the full PRESS RELEASE below.

EuropaBio Response to the Public Consultation on Blood, tissues and cells for medical treatments & therapies ’


Download
BTC-consultation-fo-website_140421_finalDownload

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.